LegoChem Biosciences Inc

LegoChem Biosciences will end the list the largest pharma companies in South Korea. LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company based in South Korea dedicated to the discovery, development, and commercialization of innovative medicines by leveraging chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases with high unmet medical needs. It is developing long-term pipelines in antibiotics, anticoagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).

The Global Team of Scientific Excellence at the organization is a highly experienced executive team with more than forty years of industry experience in medication discovery, development, and commercialization. The Best ADC Technology Award was given to a proprietary ADC technology with a demonstrated track record of global license to industry leading medicines. Its key strength is medicinal chemistry (Legochemistry), which uses fragment-based drug discovery to generate drug-like compounds faster.

The objective of LegoChem Biosciences Inc is to become a Global Top ADC firm by 2030, establishing LCB's own clinical stage pipeline, revolutionizing the platform to span the whole ADC spectrum, and becoming a pioneer with ADCs beyond traditional cancer therapy. LegoChem Biosciences is now Korea's leading company in ADC therapies, which are designed to destroy tumor cells while leaving healthy cells alone. Its ADC technology was recently recognized at an international ADC conference.

Founded: 2006
Headquarters: Daejeon, South Korea
Website: https://www.legochembio.com/